Pacira BioSciences Q4 Adjusted EPS $0.89 Beats $0.88 Estimate, Sales $181.24M Miss $181.66M Estimate
Portfolio Pulse from Benzinga Newsdesk
Pacira BioSciences (NASDAQ:PCRX) reported Q4 adjusted EPS of $0.89, beating the $0.88 estimate, but missed sales estimates with $181.24M versus the expected $181.66M. This represents a 21.92% increase in EPS and a 5.40% increase in sales from the same period last year.
February 29, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pacira BioSciences reported a Q4 adjusted EPS of $0.89, surpassing estimates, but sales of $181.24M fell short of expectations. EPS saw a significant year-over-year increase.
The beat on the EPS estimate is likely to be viewed positively by investors, indicating strong profitability. However, the slight miss on sales estimates could temper enthusiasm. The significant year-over-year growth in EPS suggests operational efficiency and growth, which could bolster investor confidence in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100